Remnant lipoprotein particles and cardiovascular disease risk

被引:15
作者
Krauss, Ronald M. [1 ]
King, Sarah M. [1 ]
机构
[1] Univ Calif San Francisco, 5700 Martin Luther KingJr Way, San Francisco, CA 94608 USA
关键词
remnant lipoproteins; chylomicrons; very low density lipoproteins; atherosclerosis; cardiovascular disease; LOW-DENSITY-LIPOPROTEIN; TRIGLYCERIDE-RICH LIPOPROTEINS; CORONARY-ARTERY-DISEASE; APOLIPOPROTEIN-CIII; NORMOTRIGLYCERIDEMIC PATIENTS; POSTPRANDIAL TRIGLYCERIDE; CHYLOMICRON REMNANTS; VLDL RECEPTOR; CHOLESTEROL; CLEARANCE;
D O I
10.1016/j.beem.2022.101682
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Intravascular catabolism of chylomicrons and very low-density li-poproteins (VLDLs) gives rise to a spectrum of partially lipolyzed remnant particles. Their plasma levels and properties are influ-enced by lipases, lipid transfer proteins, and content of exchangeable lipoproteins. Particularly important among the latter are apoE, which mediates hepatic binding and uptake of remnants, and apoCIII, which can retard this process. In the course of their plasma transit, remnants can acquire pathologic properties that promote the development of atherosclerotic cardiovascular disease (ASCVD) including increased cholesterol content and transport of thrombogenic and inflammatory mediators. Levels of cholesterol -enriched remnant particles determined by various analytic tech-niques have been significantly linked to the incidence of ASCVD, most dramatically in dyslipidemic patients homozygous for the apoE2 genetic isoform. Further research is warranted for devel-opment of clinical assays that can better capture the pathologic impact of remnant lipoprotein subspecies, and for testing the impact on ASCVD of therapies that reduce their levels.(c) 2022 Published by Elsevier Ltd.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] Lipoprotein(a) as a cardiovascular risk factor
    Katsouras, Christos S.
    Tsironis, Loukas D.
    Elisaf, Moses
    Goodevenos, John A.
    Michalis, Lampros K.
    Tselepis, Alexandros D.
    FUTURE CARDIOLOGY, 2005, 1 (04) : 509 - 517
  • [32] PCSK9 Inhibition: New Treatment Options and Perspectives to Lower Atherogenic Lipoprotein Particles and Cardiovascular Risk
    Brandts, Julia
    Mueller-Wieland, Dirk
    CURRENT ATHEROSCLEROSIS REPORTS, 2019, 21 (10)
  • [33] The relationship between lipoprotein(a) and risk of cardiovascular disease: a Mendelian randomization analysis
    Wang, Shiyue
    Zha, Li
    Chen, Jian
    Du, Dongjie
    Liu, Danyang
    Zhong, Ming
    Shang, Rongfang
    Sun, Dongxue
    Sun, Chang
    Jin, Enze
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2022, 27 (01)
  • [34] Triglycerides and remnant particles as risk factors for coronary artery disease
    Nakamura T.
    Kugiyama K.
    Current Atherosclerosis Reports, 2006, 8 (2) : 107 - 110
  • [35] High frequency of lipoprotein risk levels for cardiovascular disease in Takayasu arteritis
    de Carvalho, Jozelio Freire
    Bonfa, Eloisa
    Bezerra, Mailze C.
    Rodrigues Pereira, Rosa Maria
    CLINICAL RHEUMATOLOGY, 2009, 28 (07) : 801 - 805
  • [36] Atherogenic low-density lipoprotein and cardiovascular risk
    Hernando-Redondo, Javier
    Nino, Olga Castaner
    Fito, Montse
    CURRENT OPINION IN LIPIDOLOGY, 2025, 36 (01) : 8 - 13
  • [37] Impact of Remnant Cholesterol on Cardiovascular Risk in Diabetes
    Elias-Lopez, Daniel
    Wadstrom, Benjamin Nilsson
    Vedel-Krogh, Signe
    Kobylecki, Camilla Jannie
    Nordestgaard, Borge Gronne
    CURRENT DIABETES REPORTS, 2024, : 290 - 300
  • [38] Genetic variants and haplotypes of lipoprotein associated phospholipase A2 and their influence on cardiovascular disease (The Ludwigshafen Risk and Cardiovascular Health Study)
    Hoffmann, M. M.
    Winkler, K.
    Renner, W.
    Winkelmann, B. R.
    Seelhorst, U.
    Wellnitz, B.
    Boehm, B. O.
    Maerz, W.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 (01) : 41 - 48
  • [39] Lipoprotein(a) - Marker for cardiovascular risk and target for lipoprotein apheresis
    Klingel, Reinhard
    Heigl, Franz
    Schettler, Volker
    Roeseler, Eberhard
    Gruetzmacher, Peter
    Hohenstein, Bernd
    Vogt, Anja
    Fassbender, Cordula
    Heibges, Andreas
    Julius, Ulrich
    ATHEROSCLEROSIS SUPPLEMENTS, 2019, 40 : 17 - 22
  • [40] Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management
    Chapman, M. John
    Ginsberg, Henry N.
    Amarenco, Pierre
    Andreotti, Felicita
    Boren, Jan
    Catapano, Alberico L.
    Descamps, Olivier S.
    Fisher, Edward
    Kovanen, Petri T.
    Kuivenhoven, Jan Albert
    Lesnik, Philippe
    Masana, Luis
    Nordestgaard, Borge G.
    Ray, Kausik K.
    Reiner, Zeljko
    Taskinen, Marja-Riitta
    Tokgozoglu, Lale
    Tybjaerg-Hansen, Anne
    Watts, Gerald F.
    EUROPEAN HEART JOURNAL, 2011, 32 (11) : 1345 - 1361